Orum Therapeutics FY 2025 Annual ReportBeta
Orum Therapeutics annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Orum Therapeutics FY 2025 Annual Report Analysis
Business Overview
- • TPD² (Dual-precision Targeted Protein Degradation) technology developed combining ADC and TPD mechanisms for enhanced safety and efficacy in 2025
- • ORM-6151 (BMS-986497) licensed to Bristol Myers Squibb in Oct 2023 for relapsed/refractory AML and MDS, USD 180M deal with USD 100M received
Management Discussion & Analysis
- • Revenue KRW 23.6M (-99.89% YoY from KRW 20.9B); operating loss KRW 518B (-520.96% YoY); net loss KRW 420B (-631.15%)
- • Research & development business drove results with no new tech transfer revenue; operating loss mainly due to expanded R&D expenses
Risk Factors
- • USD foreign exchange exposure: ±KRW 799M pre-tax impact for 10% USD/KRW move in FY2025, reduced from ±KRW 2.01B in prior year
- • Liquidity risk: financial liabilities due within 1 year KRW 15.26B in FY2025, up from KRW 4.21B in prior year
Orum Therapeutics FY 2025 Key Financial MetricsDART
Total Assets
KRW 169.3B
▲ +10.1% YoY
Operating Cash Flow
-KRW 36.0B
▼ -219.0% YoY
Source: KIFRS consolidated financial data from Orum Therapeutics annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding